- Home
- GGN vs RIGL Comparison
GGN vs RIGL Comparison
Compare GGN & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGN | RIGL |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.0M | 884.9M |
| IPO Year | 2005 | 2000 |
Fundamental Metrics
Financial Performance| Metric | GGN | RIGL |
|---|---|---|
| Price | $5.49 | $46.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $45.67 |
| AVG Volume (30 Days) | ★ 523.0K | 207.1K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 10.26% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ N/A | $34.73 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $4.63 | $24.84 |
| 52 Week High | $5.88 | $52.24 |
Technical Indicators
Market Signals| Indicator | GGN | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 49.53 | 53.35 |
| Support Level | $5.42 | $40.50 |
| Resistance Level | $5.73 | $49.50 |
| Average True Range (ATR) | 0.07 | 1.46 |
| MACD | -0.04 | -0.53 |
| Stochastic Oscillator | 36.62 | 34.48 |
Price Performance
Historical ComparisonAbout GGN GAMCO Global Gold Natural Resources & Income Trust
GAMCO Global Gold Natural Resources & Income Trust is a non-diversified closed-end management investment company. Its primary investment objective is to provide a high current income and capital appreciation as its secondary objective. To achieve its objective, the fund may invest majority of its assets in equity securities of companies principally engaged in the gold and natural resources industries. It also intends to earn income through an option planning of writing (selling) covered call options on equity securities in its portfolio.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.